Generic CEOs Need To Act Like Brand Execs, Association Head Says
AAM President Davis, a PhRMA veteran, says personal engagement – in addition to lobbying spending – is key to successful policy advocacy.
You may also be interested in...
Incoming Office of Generic Drugs Director Sally Choe is largely unfamiliar to industry, but potentially offers a new perspective.
FDA's Biosimilar Action Plan aims to boost approvals, but Commissioner Gottlieb says he's had a change of heart about how much impact an interchangeability designation can have on market uptake.
Discussions through the WHO are aimed at educating low- and middle-income countries, while efforts with ‘the larger regulators’ aim to reduce the development burden for products targeting ultra-rare diseases, CBER director Peter Marks tell DIA.